StockDuty ← Dashboard Oct 02, 2026 02:37 PM ET
CatalystFDA/Bio

Foghorn Therapeutics is cutting 40% of its workforce after Eli Lilly ends cancer drug partnership

Eli Lilly ending cancer drug partnership triggers 40% workforce cut at Foghorn Therapeutics.

What changed
Eli Lilly ending cancer drug partnership triggers 40% workforce cut at Foghorn Therapeutics.
Why it matters
Eli Lilly ending cancer drug partnership triggers 40% workforce cut at Foghorn Therapeutics. — impact context not separately stored; see What changed.
Sources
qz
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →